Dasatinib Monohydrate: Multitargeted Tyrosine Kinase Inhibitor for CML Research

Executive Summary: Dasatinib Monohydrate (BMS-354825) is an ATP-competitive kinase inhibitor primarily targeting ABL, SRC, KIT, and PDGFR, with nanomolar potency (IC50: 0.55 nM for Src, 3.0 nM for Bcr-Abl) [APExBIO]. It effectively inhibits both nonmutated and imatinib-resistant BCR-ABL isoforms, making it a reference tool for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) leukemias (Telerman et al., 2022). In vitro, it exhibits broad-spectrum antiproliferative effects on hematological and solid tumor lines. In vivo, dasatinib reduces CML progression and BCR-ABL-driven disease markers in murine models. It is clinically approved for Ph+ CML and acute lymphoblastic leukemia (ALL) since 2006, with defined storage and solubility parameters for laboratory use [APExBIO].

Biological Rationale

Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 fusion gene, resulting from the t(9;22)(q34;q11) Philadelphia chromosome translocation. This fusion produces a constitutively active tyrosine kinase that drives uncontrolled proliferation and survival of myeloid cells (Telerman et al., 2022). Tyrosine kinase inhibitors (TKIs) have transformed CML treatment paradigms by targeting aberrant BCR-ABL signaling. However, resistance due to point mutations in the BCR-ABL kinase domain, particularly the T315I mutation, necessitates multitargeted agents with efficacy against a broader mutation spectrum [1]. Dasatinib Monohydrate directly addresses this need by inhibiting both wild-type and multiple imatinib-resistant BCR-ABL isoforms. Its broad kinase inhibition profile also modulates related signaling pathways implicated in disease progression and drug resistance, including SRC family kinases, KIT, and PDGFR.

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate is an orally bioavailable, multitargeted tyrosine kinase inhibitor. It acts as an ATP-competitive antagonist, binding to the kinase domain of ABL, SRC, KIT, PDGFR, and several other tyrosine kinases. Its inhibition of BCR-ABL occurs at nanomolar concentrations (IC50 for BCR-ABL: 3.0 nM) [APExBIO]. Dasatinib also potently inhibits SRC-family kinases (IC50 for SRC: 0.55 nM), which play roles in cytoskeletal organization, migration, and leukemic cell adhesion. By targeting multiple kinases, dasatinib blocks downstream signaling pathways essential for leukemic cell survival, proliferation, and microenvironmental interactions. In CML models, dasatinib suppresses BCR-ABL-induced neutrophil extracellular trap (NET) formation, a process linked to thrombosis and disease progression (Telerman et al., 2022). The compound is structurally defined as C22H28ClN7O3S with a molecular weight of 506.02 and is formulated as a monohydrate for enhanced stability and handling.

Evidence & Benchmarks

• Dasatinib Monohydrate inhibits BCR-ABL kinase at an IC50 of 3.0 nM, and SRC kinase at 0.55 nM, in cell-free kinase assays (APExBIO).
• It is effective against both nonmutated and imatinib-resistant BCR-ABL isoforms, including T315I, in engineered cell assays and patient-derived cells (Telerman et al., 2022).
• Dasatinib is clinically approved by the FDA since 2006 for all phases of Ph+ CML and Ph+ acute lymphoblastic leukemia (ALL) (FDA label).
• In vitro, dasatinib inhibits proliferation of hematological and solid tumor cell lines at sub-micromolar concentrations (APExBIO).
• In vivo, dasatinib significantly reduces disease progression and bioluminescent signals in mouse models with BCR-ABL mutations (Telerman et al., 2022).
• Dasatinib differentially affects neutrophil extracellular trap (NET) formation compared to other TKIs, modulating pro-thrombotic risk in CML (Telerman et al., 2022).

Applications, Limits & Misconceptions

Dasatinib Monohydrate is a reference tool for:

• Chronic myeloid leukemia (CML) and Ph+ ALL research, especially in drug-resistant contexts.
• Dissecting tyrosine kinase signaling pathways and SRC-family kinase biology.
• In vitro and in vivo modeling of kinase-driven drug resistance and microenvironment crosstalk.
• Personalized medicine workflows using patient-derived assembloid or xenograft models.

For an in-depth discussion of assembloid applications and microenvironmental resistance, see "Dasatinib Monohydrate: Advancing Personalized Cancer Drug..."; this article extends those findings by detailing mechanistic NET modulation and precise kinase inhibition data. For translational perspectives on resistance in solid tumors, refer to "Dasatinib Monohydrate: Redefining Personalized Kinase Inh...", which this article updates with recent benchmarks on BCR-ABL and SRC inhibition.

Common Pitfalls or Misconceptions

• Dasatinib Monohydrate is not effective against all forms of kinase-driven resistance (e.g., certain compound BCR-ABL mutations remain refractory).
• It is insoluble in ethanol and water; DMSO is required for stock preparation at ≥25.3 mg/mL (APExBIO).
• Long-term storage of solutions (>1 week at -20°C) can reduce compound stability and potency.
• Dasatinib is not a substrate-specific probe; its multitargeted profile may confound pathway attribution in complex models.
• It cannot reverse established cardiovascular complications associated with some TKI therapies (Telerman et al., 2022).

Workflow Integration & Parameters

For laboratory workflows, Dasatinib Monohydrate (SKU: B5954, APExBIO) should be prepared in DMSO at ≥25.3 mg/mL and stored at -20°C. Working solutions should be freshly prepared and used within one week for optimal activity. Recommended in vitro dosing ranges from 0.1–100 nM, depending on cell type and assay design. For in vivo mouse studies, dosing regimens should follow published pharmacokinetic and toxicity profiles. The multitargeted nature of dasatinib enables its use in assembloid, co-culture, and xenograft models to interrogate kinase signaling, resistance, and microenvironmental effects. For troubleshooting or advanced protocol guidance, the article "Dasatinib Monohydrate: Advanced Applications in Tumor Ass..." provides detailed workflow strategies; this dossier supplements those protocols with molecular specificity data and stability notes.

Conclusion & Outlook

Dasatinib Monohydrate is a validated, multitargeted tyrosine kinase inhibitor with robust efficacy against BCR-ABL and SRC kinases at nanomolar concentrations. It is a gold-standard tool for CML research, particularly in drug-resistant and translational contexts. Proper handling and dosing are critical for reproducible results. Future research will clarify its roles in modulating NET formation, thrombosis risk, and kinase crosstalk in complex tumor microenvironments. For product specifications and ordering information, refer to the official APExBIO product page.